• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/16/21 3:52:46 PM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRTC alert in real time by email
    SC 13G 1 puretechhealthplc.htm
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13D-1(b) AND
    AMENDMENTS FILED THERETO FILED PURSUANT TO RULE 13D-2(b)
    Under the Securities Exchange Act of 1934
    (Amendment No. _)*
    PureTech Health PLC
     (Name of Issuer)

    Common Stock
    (Title of Classes of Securities)
    G7297M101
    (CUSIP Number)

    December 31, 2020
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    : Rule 13d-1(b)
    :    Rule 13d-1(c)
    :X   Rule 13d-1(d)


    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    CUSIP No.:G7297M101
    1
    NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
     
    Invesco Ltd.
    IRS # 980557567
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a)
    (b)
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Invesco Ltd. – Bermuda
              NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
    5
     
    SOLE VOTING POWER – 80,230,013
     
     
    6
     
    SHARED VOTING POWER – 0
     
     
    7
     
    SOLE DISPOSITIVE POWER – 80,230,013
     
     
    8
     
    SHARED DISPOSITIVE POWER – 0
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    80,230,013
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
     
    N/A
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
     
    28.07%
    12
    TYPE OF REPORTING PERSON*
     
    See Item 3 of this statement

    Item 1(a). Name of Issuer:
    PureTech Health PLC
    (b). Address of Issuer’s Principal Executive Offices:
    6 Tide Street, Boston, MA 02210, United States
    Item 2(a). Name of Person Filing:
    Invesco Ltd.
    (b). Address of Principal Business Office or, if none, residence of filing person:
    1555 Peachtree Street NE; Atlanta, GA 30309; United States
    (c). Citizenship of filing person:
    Bermuda
    (d). Title of Classes of Securities:
    Common Stock

    (e). CUSIP Number:
    G7297M101

    Item 3. If this statement is filed pursuant to ss240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (e) [x] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E)

    (g) [x] A parent holding company or control person in accordance with section 240.13d-1(b)(1)(ii)(G)

    Item 4. Ownership:

    Please see responses to Items 5-8 on the cover of this statement, which are incorporated herein by reference.

    Item 5. Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ]

    Item 6. Ownership of More than Five Percent on Behalf of Another Person:

    Invesco Asset Management Ltd. is a subsidiary of Invesco Ltd. and it advises the Invesco UK Equity High Income which owns 15.68% of the security reported herein. Invesco Asset Management Ltd. is a subsidiary of Invesco Ltd. and it advises the Invesco UK Equity High Income Fund which owns 9.08% of the security reported herein. However, no one individual has greater than 5% economic ownership. The shareholders of the Fund have the right to receive or the power to direct the receipt of dividends and proceeds from the sale of securities listed above.


    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company:

    The following subsidiaries of Invesco Ltd. are investment advisers which hold shares of the security being reported:

    Invesco Asset Management Ltd.

    Item 8. Identification and Classification of Members of the Group:

    N/A

    Item 9. Notice of Dissolution of a Group:

    N/A

    Item 10. Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Signature:

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    02/16/2020
    Date

    Invesco Ltd.

    By:  /s/ Robert R. Leveille
    Robert R. Leveille
    Global Assurance Officer

    Get the next $PRTC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRTC

    DatePrice TargetRatingAnalyst
    9/9/2024$58.00 → $45.00Outperform
    Leerink Partners
    1/7/2022$76.00 → $70.00Outperform
    SVB Leerink
    8/25/2021$74.00 → $76.00Outperform
    SVB Leerink
    More analyst ratings

    $PRTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PureTech Health: Notice of Half-Yearly Results

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company") plans to announce its half-yearly results for the six months ended June 30, 2025, on Thursday, August 28, 2025. A presentation and conference call for analysts and shareholders will take place at 9:00am EDT / 2:00pm BST on the day of publication, and a webcast of the presentation will be available on the Company's website at https://investors.puretechhealth.com/events-presentations. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep port

    8/18/25 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint

    VE202 was well tolerated, with no reports of treatment-related serious adverse events Additional analyses from COLLECTiVE202 to be shared in upcoming scientific forums Vedanta to focus resources on ongoing Phase 3 RESTORATiVE303 registrational study of VE303 in recurrent Clostridioides difficile infection PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech"), noted that its Founded Entity, Vedanta Biosciences, ("Vedanta") a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases, today announced that its candidate VE202 did not meet the primary endpoint in the Phase 2 COLLECTiVE202 study for the treatment of patients

    8/13/25 12:16:00 PM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases

    Former Teva North America CEO Sven Dethlefs, PhD, to lead Celea PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced the launch of a new Founded Entity Celea Therapeutics ("Celea"). Celea's mission is to deliver therapies that transform the lives of people with serious respiratory diseases. Its lead program, deupirfenidone (LYT-100), is a Phase 3-ready therapeutic candidate that holds promise across multiple fibrotic and inflammatory lung conditions and is initially being advanced for the treatment of idiopathic pulmonary fibrosis (IPF),

    8/12/25 7:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTC
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by PureTech Health plc

    SCHEDULE 13G - PureTech Health plc (0001782999) (Subject)

    8/11/25 1:05:29 PM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by PureTech Health plc

    6-K - PureTech Health plc (0001782999) (Filer)

    7/16/25 6:30:13 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by PureTech Health plc

    6-K - PureTech Health plc (0001782999) (Filer)

    7/8/25 4:15:37 PM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners resumed coverage on PureTech Health plc with a new price target

    Leerink Partners resumed coverage of PureTech Health plc with a rating of Outperform and set a new price target of $45.00 from $58.00 previously

    9/9/24 7:42:36 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVB Leerink reiterated coverage on PureTech Health with a new price target

    SVB Leerink reiterated coverage of PureTech Health with a rating of Outperform and set a new price target of $70.00 from $76.00 previously

    1/7/22 4:34:06 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVB Leerink reiterated coverage on PureTech Health with a new price target

    SVB Leerink reiterated coverage of PureTech Health with a rating of Outperform and set a new price target of $76.00 from $74.00 previously

    8/25/21 4:40:14 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by PureTech Health plc

    SC 13G - PureTech Health plc (0001782999) (Subject)

    11/12/24 1:29:13 PM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PureTech Health plc

    SC 13G/A - PureTech Health plc (0001782999) (Subject)

    11/7/24 9:47:57 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by PureTech Health plc (Amendment)

    SC 13G/A - PureTech Health plc (0001782999) (Subject)

    2/12/24 4:48:30 PM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTC
    Financials

    Live finance-specific insights

    View All

    PureTech Health: Notice of Half-Yearly Results

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company") plans to announce its half-yearly results for the six months ended June 30, 2025, on Thursday, August 28, 2025. A presentation and conference call for analysts and shareholders will take place at 9:00am EDT / 2:00pm BST on the day of publication, and a webcast of the presentation will be available on the Company's website at https://investors.puretechhealth.com/events-presentations. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep port

    8/18/25 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Health: Notice of Results

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December 31, 2024, on Wednesday, April 30, 2025. A presentation and conference call to discuss the results will take place at 9:00 AM EDT / 2:00 PM BST on the day of publication, and a webcast of the presentation will be available on the Company's website at https://investors.puretechhealth.com/events-presentations. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a b

    4/23/25 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech's Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial

    Dose-ranging trial evaluated deupirfenidone 550 mg three times a day (TID) (approximately equivalent exposure to pirfenidone 801 mg TID1) and deupirfenidone 825 mg TID and successfully demonstrated dose-dependent response Decline in lung function seen with deupirfenidone 825 mg TID as a monotherapy was -21.5 mL; natural lung function decline expected in healthy adults >60 years is ~-15 to ~-25 mL2; decline in lung function with pirfenidone 801 mg TID was -51.6 mL Deupirfenidone 825 mg TID showed strong, consistent and durable efficacy with a treatment effect versus placebo of 80.9% with favorable tolerability, while pirfenidone 801 mg TID had a 54.1% treatment effect versus placebo De

    12/16/24 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTC
    Leadership Updates

    Live Leadership Updates

    View All

    PureTech Announces Leadership Transition

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, announces that Bharatt Chowrira, PhD, JD, has stepped down today from his role as Chief Executive Officer (CEO) and as a member of the Board of Directors. The Board of Directors has appointed Robert Lyne as Interim CEO with effect from today. Mr. Lyne joined PureTech as Chief Portfolio Officer in January 2024 and is an experienced leader of UK-listed life science innovation and venture capital companies, having previously served as CEO of Arix Bioscience plc. He will continue to work closely with PureTe

    7/16/25 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Appoints Peel Hunt as Joint UK Corporate Broker

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), is pleased to announce that it has appointed Peel Hunt as Joint UK Corporate Broker alongside UBS. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeut

    4/9/25 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

    3/11/25 7:05:00 AM ET
    $BAX
    $BMRN
    $EMBC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities